Corcept Therapeutics reports Q1 EPS 14c, consensus 19c
The Fly

Corcept Therapeutics reports Q1 EPS 14c, consensus 19c

Reports Q1 revenue $ $105.65M , consensus $104.87M. Cash and investments were $465.1M at March 31 compared to $436.6M at December 31. In April, Corcept purchased 6.6M shares of its common stock for $145.4M. "Korlym is an excellent treatment for patients with Cushing’s syndrome and there are many eligible patients who have yet to receive it. We are making substantial investments to improve the ability of physicians to identify and treat patients with hypercortisolism, most notably our recently established CATALYST study, and are optimistic about the growth of our Cushing’s syndrome business. We are raising our 2023 revenue guidance to $435M – $455M ," said Joseph K. Belanoff, MD, Corcept’s Chief Executive Officer.Clinical Development

Published first on TheFly

See today’s best-performing stocks on TipRanks >>

Read More on CORT:

Related Articles
TheFlyCorcept Therapeutics price target raised to $67 from $38 at Piper Sandler
TheFlyBiotech Alert: Searches spiking for these stocks today
TheFlyCorcept Therapeutics price target raised to $78 from $38 at Canaccord
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App